Clinical Trial

Open-Label Study of AG10 in Patients with Cardiomyopathy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-05-23; most recent amendment 2025-03-11.
Status change: Enrolling by Invitation → Active, Not Recruiting 2021-09-15
Trial Details
NCT Number NCT03536767
Lead Sponsor Eidos Therapeutics, a BridgeBio company
Conditions Amyloid Cardiomyopathy
Enrollment 55 participants
Start Date 2018-08-08
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-13